Quizartinib (AC220): a promising option for acute myeloid leukemia

References

• Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358–2365. Epub 2006/06/10. doi:10.1182/blood-2006-02-00347516763210
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474. Epub 2009/11/03. doi:10.1182/blood-2009-07-23535819880497
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. Epub 2015/09/17. doi:10.1056/NEJMra140618426376137
   PubMed Web of Science ®Google Scholar
• Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3 Epub 2018/01/06. doi:10.1186/s13045-017-0543-729301553
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X29339097
   PubMed Web of Science ®Google Scholar
• Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol. 2019;94(3):358–362. doi:10.1002/ajh.2536930499168
   PubMed Web of Science ®Google Scholar
• Song Y, Magenau J, Li Y, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016;51(4):511–520. Epub 2015/ 07/21. doi:10.1038/bmt.2015.17026191952
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. Epub 2016/11/30. doi:10.1182/blood-2016-08-73319627895058
   PubMed Web of Science ®Google Scholar
• Ouchida AT, Li Y, Geng J, et al. Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. Cell Death Dis. 2018;9(2):138 Epub 2018/01/28. doi:10.1038/s41419-017-0170-929374185
   PubMed Web of Science ®Google Scholar
• Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS One. 2015;10(4):e0121177 Epub 2015/04/04. doi:10.1371/journal.pone.012117725837374
   PubMed Web of Science ®Google Scholar
• Larrue C, Saland E, Boutzen H, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127(7):882–892. Epub 2015/08/20. doi:10.1182/blood-2015-05-64649726286850
   PubMed Web of Science ®Google Scholar
• Kapoor S, Natarajan K, Baldwin PR, et al. Concurrent inhibition of pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation. Clin Cancer Res. 2018;24(1):234–247. Epub 2017/ 10/28. doi:10.1158/1078-0432.ccr-17-162929074603
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Schnetzke U, Schrenk KG, et al. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2017;143(2):337–345. doi:10.1007/s00432-016-2290-527778197
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93(2):222–231. doi:10.1002/ajh.2495929090473
   PubMed Web of Science ®Google Scholar
• Carow CE, Kim E, Hawkins AL, et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12–>q13. Cytogenet Cell Genet. 1995;70(3–4):255–257. doi:10.1159/0001340467789184
   PubMedGoogle Scholar
• Vandergeer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal-transduction pathways. Annu Rev Cell Biol. 1994;10:251–337. doi:10.1146/annurev.cellbio.10.1.2517888178
   PubMedGoogle Scholar
• Rosnet O, Buhring HJ, de Lapeyriere O, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 1996;95(3–4):218–223. doi:10.1159/0002038818677746
   PubMed Web of Science ®Google Scholar
• Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014;5(3):65–77. doi:10.1177/204062071453212324883179
   PubMedGoogle Scholar
• Small D, Levenstein M, Kim E, et al. Stk-1, the human homolog of Flk-2/Flt-3, is selectively expressed in Cd34(+) human bone-marrow cells and is involved in the proliferation of early progenitor stem-cells. Proc Natl Acad Sci USA. 1994;91(2):459–463. doi:10.1073/pnas.91.2.4597507245
   PubMed Web of Science ®Google Scholar
• Gu JY, Gu X. Natural history and functional divergence of protein tyrosine kinases. Gene. 2003;317(1–2):49–57. doi:10.1016/S0378-1119(03)00696-614604791
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. FLT3: iTDoes matter in leukemia. Leukemia. 2003;17(9):1738–1752. doi:10.1038/sj.leu.240309912970773
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21(16):2555–2563. doi:10.1038/sj/onc/120533211971190
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12(9):1333–1337. doi:10.1038/sj.leu.24011309737679
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2):169–178. doi:10.1016/S1097-2765(03)00505-714759363
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Gene Dev. 2004;18(16):1926–1945. doi:10.1101/gad.121270415314020
   PubMed Web of Science ®Google Scholar
• Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68(2):320–344. doi:10.1128/MMBR.68.2.320-344.200415187187
   PubMed Web of Science ®Google Scholar
• Bar-Natan M, Nelson EA, Xiang M, Frank DA. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT. 2012;1(2):55–64. doi:10.4161/jkst.2000624058751
   PubMedGoogle Scholar
• Hassanein M, Almahayni MH, Ahmed SO, Gaballa S, El Fakih R. FLT3 inhibitors for treating acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(10):543–549. doi:10.1016/j.clml.2016.06.00227450971
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66. doi:10.1182/blood.V100.1.5912070009
   PubMed Web of Science ®Google Scholar
• Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012;26(10):2176–2185. doi:10.1038/leu.2012.11422614177
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089–5102. doi:10.1182/blood-2010-04-26186720705759
   PubMed Web of Science ®Google Scholar
• Stockard B, Guingab J, Garrett T, Pounds S, Rubnitz JE, Lamba J. Global and targeted metabolic profiling identifies metabolic markers for FLT3-ITD in pediatric AML patients. Blood. 2017;130. PubMed PMID:WOS:000432419705282.
   Google Scholar
• Small D. FLT3: biology and molecular targeting to improve outcome in AML. Pediatr Blood Cancer. 2017;64:S2–S.
   Web of Science ®Google Scholar
• Adamia S, Nemeth J, Bhatt S, et al. FLT3 Splice Variant (FLT3Va) as a potential immunotherapeutic target in patients with Acute Myeloid Leukemia (AML). Blood. 2016;128(22). doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Dany M, Gencer S, Nganga R, et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016;128(15):1944–1958. doi:10.1182/blood-2016-04-70875027540013
   PubMed Web of Science ®Google Scholar
• Kazi JU, Chougule RA, Li TF, et al. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. Cell Mol Life Sci. 2017;74(14):2679–2688. doi:10.1007/s00018-017-2494-028271164
   PubMed Web of Science ®Google Scholar
• Matthews W, Jordan CT, Gw W, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65(7):1143–1152.1648448
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013;22(12):1659–1669. doi:10.1517/13543784.2013.842973
   PubMed Web of Science ®Google Scholar
• Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol. 2013;97(6):683–694. doi:10.1007/s12185-013-1334-823613268
   PubMed Web of Science ®Google Scholar
• Chao Q, Sprankle KG, Grotzfeld RM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N ‘-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-Like Tyrosine Kinase-3 (FLT3) inhibitor. J Med Chem. 2009;52(23):7808–7816. doi:10.1021/jm900753319754199
   PubMed Web of Science ®Google Scholar
• Hills RK, Gammon G, Trone D, Burnett AK. Quizartinib significantly improves overall survival in FLT3-ITD positive AML patients relapsed after stem cell transplantation or after failure of salvage chemotherapy: a comparison with historical AML database (UK NCRI data). Blood. 2015;126(23). PubMed PMID: WOS:000368020102069.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Ben-Ami E, Patnaik A, Trone D, Li JK, Demetri GD. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer. 2018;18(1):790. doi:10.1186/s12885-018-4242-830081867
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681-+. doi:10.1200/Jco.2013.48.8783
   Web of Science ®Google Scholar
• Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984–2992. doi:10.1182/blood-2009-05-22203419654408
   PubMed Web of Science ®Google Scholar
• Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–U153. doi:10.1038/nature1101622504184
   PubMed Web of Science ®Google Scholar
• Levis MJ, Cortes JE, Gammon GM, Trone D, Kang DW, Li JK. Laboratory and clinical investigations to identify the optimal dosing strategy for quizartinib (AC220) monotherapy in FLT3-Itd-positive (+) relapsed/refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 2016;128(22). doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213–221. doi:10.1002/ajh.2497429139135
   PubMed Web of Science ®Google Scholar
• Swaminathan M, Kantarjian HM, Daver N, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;130. PubMed PMID:WOS:000432419401370.
   Google Scholar
• Sanga M, James J, Marini J, Gammon G, Hale C, Li JK. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica. 2017;47(10):856–869. doi:10.1080/00498254.2016.121710027460866
   PubMed Web of Science ®Google Scholar
• Cortes J, Perl AE, Dohner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903. doi:10.1016/S1470-2045(18)30240-729859851
   PubMed Web of Science ®Google Scholar
• Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598–607. doi:10.1182/blood-2018-01-82162929875101
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1056/NEJMoa161435928644114
   PubMed Web of Science ®Google Scholar
• Martin MT, Jeschke G, Perl AE, Carroll M, Figueroa ME. Differentiation response to quizartinib, a potent 2nd generation FLT3 inhibitor, in relapsed FLT3-mutant AML patients correlates with specific DNA methylation signature prior to therapy. Blood. 2017;130. PubMed PMID:WOS:000432419401370.
   Google Scholar
• Khaled S, Ganguly S, Perl AE, et al. Concordance between bone marrow and peripheral blood samples for assessment of FLT3 Internal Tandem Duplication (ITD) mutations: data from patients screened for participation in quantum-R, a global, randomized, open-label, phase 3 study examining the effect of quizartinib monotherapy vs salvage chemotherapy on overall survival in patients with FLT3 – ITD – mutated AML who are refractory to or have relapsed after first-line therapy. Blood. 2017;130. PubMed PMID:WOS:000432419403248.
   Google Scholar
• Schlenk R, Dombret H, Amadori S, et al. QuANTUM-first: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). Ann Oncol. 2017;28. doi:10.1093/annonc/mdx075
   Web of Science ®Google Scholar
• Smith CC, Paguirigan A, Jeschke GR, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130(1):48–58. doi:10.1182/blood-2016-04-71182028490572
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60. doi:10.1182/blood-2004-03-089115345597
   PubMed Web of Science ®Google Scholar
• Hirade T, Abe M, Onishi C, Taketani T, Yamaguchi S, Fukuda S. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by up-regulating RUNX1 expression in hematopoietic cells. Int J Hematol. 2016;103(1):95–106. doi:10.1007/s12185-015-1908-826590920
   PubMed Web of Science ®Google Scholar
• Hou PP, Wu C, Wang YC, et al. A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res. 2017;77(16):4402–4413. doi:10.1158/0008-5472.Can-16-162728625976
   PubMed Web of Science ®Google Scholar
• Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016;76(22):6471–6482. doi:10.1158/0008-5472.Can-15-356927671675
   PubMed Web of Science ®Google Scholar
• Abe M, Pelus LM, Singh P, et al. Internal tandem duplication in FLT3 attenuates proliferation and regulates resistance to the FLT3 inhibitor AC220 by modulating p21Cdkn1a and Pbx1 in hematopoietic cells. PLoS One. 2016;11(7):e0158290. doi:10.1371/journal.pone.015829027387666
   PubMed Web of Science ®Google Scholar
• Friedman R. The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib. Proteins. 2017;85(11):2143–2152. doi:10.1002/prot.2536828799176
   PubMed Web of Science ®Google Scholar
• Verma S, Singh A, Kumari A, et al. Insight into the inhibitor discrimination by FLT3 F691L. Chem Biol Drug Des. 2018;91(5):1056–1064. doi:10.1111/cbdd.1316929336115
   PubMed Web of Science ®Google Scholar
• Levis M. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol. 2014;10(9):1571–1579. doi:10.2217/Fon.14.10525145428
   PubMed Web of Science ®Google Scholar
• Suarasan S, Simon T, Boca S, Tomuleasa C, Astilean S. Gelatin-coated gold nanoparticles as carriers of FLT3 inhibitors for acute myeloid leukemia treatment. Chem Biol Drug Des. 2016;87(6):927–935. doi:10.1111/cbdd.1272526808072
   PubMed Web of Science ®Google Scholar
• Li GX, Wang L, Yaghmour B, Ramsingh G, Yaghmour G. The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant. Leuk Res Rep. 2018;10:26–36. doi:10.1016/j.lrr.2018.06.00330112274
   PubMedGoogle Scholar
• Cortes J Quizartinib significantly prolongs overall survival in pa‐ tients with FLT3‐internal tandem duplication–mutated (mut) re‐ lapsed/refractory aml in the phase 3, randomized, controlled quantum‐r trial. EHA Learning Center. Abstract LB2600; 2018 Available from: . Accessed 6, 2018.
   Google Scholar